Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen

Giorgio Cocconi, Mariangela Bella, Federico Calabresi, Maurizio Tonato, Rodolfo Canaletti, Corrado Boni, Franco Buzzi, Guido Ceci, Enrichetta Corgna, Paolo Costa, Renata Lottici, Franco Papadia, Maria Carla Sofra, Marisa Bacchi

Research output: Contribution to journalArticle

Abstract

Background. Endocrine factors may affect the clinical course of malignant melanoma and the response to the treatment of this disease. The presence of estrogen receptors in melanomas has been suggested, and occasional responses to antiestrogen therapy have been reported. Methods and Results. We randomly assigned 117 patients with metastatic malignant melanoma to treatment with dacarbazine alone or dacarbazine in combination with tamoxifen. The overall rate of response, measured objectively, was higher (28 percent vs. 12 percent, P = 0.03) and survival was longer (median, 48 vs. 29 weeks, P = 0.02) among the patients who received dacarbazine plus tamoxifen than among those who received dacarbazine alone. Among women, both the response rate (38 percent vs. 10 percent, P = 0.04) and the median survival (69 vs. 30 weeks, P = 0.008) were better with dacarbazine plus tamoxifen than with dacarbazine alone, whereas among men the differences were smaller and not statistically significant. Among the patients given dacarbazine alone, there were no significant differences between women and men in response rate (10 percent vs. 13 percent) or survival (30 vs. 27 weeks), whereas among those given dacarbazine plus tamoxifen, women had better outcomes, as indicated by both response rate (38 percent vs. 19 percent, P = 0.15) and survival (69 vs. 31 weeks, P = 0.02). When we analyzed the Quetelet body-mass index (the weight in kilograms divided by the square of the height in meters) as an indirect indicator of the levels of endogenous estrogens in postmenopausal women and in men, survival was not affected by the body-mass index in the group given dacarbazine alone, whereas in the group given dacarbazine plus tamoxifen, survival was longer among patients whose Quetelet index was above the median value than among those with a Quetelet index lower than the median value (60 vs. 26 weeks, P

Original languageEnglish
Pages (from-to)516-523
Number of pages8
JournalNew England Journal of Medicine
Volume327
Issue number8
Publication statusPublished - Aug 20 1992

Fingerprint

Dacarbazine
Tamoxifen
Melanoma
Survival
Body Mass Index
Therapeutics
Estrogen Receptor Modulators
Estrogen Receptors
Estrogens
Weights and Measures

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cocconi, G., Bella, M., Calabresi, F., Tonato, M., Canaletti, R., Boni, C., ... Bacchi, M. (1992). Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. New England Journal of Medicine, 327(8), 516-523.

Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. / Cocconi, Giorgio; Bella, Mariangela; Calabresi, Federico; Tonato, Maurizio; Canaletti, Rodolfo; Boni, Corrado; Buzzi, Franco; Ceci, Guido; Corgna, Enrichetta; Costa, Paolo; Lottici, Renata; Papadia, Franco; Sofra, Maria Carla; Bacchi, Marisa.

In: New England Journal of Medicine, Vol. 327, No. 8, 20.08.1992, p. 516-523.

Research output: Contribution to journalArticle

Cocconi, G, Bella, M, Calabresi, F, Tonato, M, Canaletti, R, Boni, C, Buzzi, F, Ceci, G, Corgna, E, Costa, P, Lottici, R, Papadia, F, Sofra, MC & Bacchi, M 1992, 'Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen', New England Journal of Medicine, vol. 327, no. 8, pp. 516-523.
Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. New England Journal of Medicine. 1992 Aug 20;327(8):516-523.
Cocconi, Giorgio ; Bella, Mariangela ; Calabresi, Federico ; Tonato, Maurizio ; Canaletti, Rodolfo ; Boni, Corrado ; Buzzi, Franco ; Ceci, Guido ; Corgna, Enrichetta ; Costa, Paolo ; Lottici, Renata ; Papadia, Franco ; Sofra, Maria Carla ; Bacchi, Marisa. / Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. In: New England Journal of Medicine. 1992 ; Vol. 327, No. 8. pp. 516-523.
@article{30f9cf07d7f34e3c93e736afab31be26,
title = "Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen",
abstract = "Background. Endocrine factors may affect the clinical course of malignant melanoma and the response to the treatment of this disease. The presence of estrogen receptors in melanomas has been suggested, and occasional responses to antiestrogen therapy have been reported. Methods and Results. We randomly assigned 117 patients with metastatic malignant melanoma to treatment with dacarbazine alone or dacarbazine in combination with tamoxifen. The overall rate of response, measured objectively, was higher (28 percent vs. 12 percent, P = 0.03) and survival was longer (median, 48 vs. 29 weeks, P = 0.02) among the patients who received dacarbazine plus tamoxifen than among those who received dacarbazine alone. Among women, both the response rate (38 percent vs. 10 percent, P = 0.04) and the median survival (69 vs. 30 weeks, P = 0.008) were better with dacarbazine plus tamoxifen than with dacarbazine alone, whereas among men the differences were smaller and not statistically significant. Among the patients given dacarbazine alone, there were no significant differences between women and men in response rate (10 percent vs. 13 percent) or survival (30 vs. 27 weeks), whereas among those given dacarbazine plus tamoxifen, women had better outcomes, as indicated by both response rate (38 percent vs. 19 percent, P = 0.15) and survival (69 vs. 31 weeks, P = 0.02). When we analyzed the Quetelet body-mass index (the weight in kilograms divided by the square of the height in meters) as an indirect indicator of the levels of endogenous estrogens in postmenopausal women and in men, survival was not affected by the body-mass index in the group given dacarbazine alone, whereas in the group given dacarbazine plus tamoxifen, survival was longer among patients whose Quetelet index was above the median value than among those with a Quetelet index lower than the median value (60 vs. 26 weeks, P",
author = "Giorgio Cocconi and Mariangela Bella and Federico Calabresi and Maurizio Tonato and Rodolfo Canaletti and Corrado Boni and Franco Buzzi and Guido Ceci and Enrichetta Corgna and Paolo Costa and Renata Lottici and Franco Papadia and Sofra, {Maria Carla} and Marisa Bacchi",
year = "1992",
month = "8",
day = "20",
language = "English",
volume = "327",
pages = "516--523",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "8",

}

TY - JOUR

T1 - Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen

AU - Cocconi, Giorgio

AU - Bella, Mariangela

AU - Calabresi, Federico

AU - Tonato, Maurizio

AU - Canaletti, Rodolfo

AU - Boni, Corrado

AU - Buzzi, Franco

AU - Ceci, Guido

AU - Corgna, Enrichetta

AU - Costa, Paolo

AU - Lottici, Renata

AU - Papadia, Franco

AU - Sofra, Maria Carla

AU - Bacchi, Marisa

PY - 1992/8/20

Y1 - 1992/8/20

N2 - Background. Endocrine factors may affect the clinical course of malignant melanoma and the response to the treatment of this disease. The presence of estrogen receptors in melanomas has been suggested, and occasional responses to antiestrogen therapy have been reported. Methods and Results. We randomly assigned 117 patients with metastatic malignant melanoma to treatment with dacarbazine alone or dacarbazine in combination with tamoxifen. The overall rate of response, measured objectively, was higher (28 percent vs. 12 percent, P = 0.03) and survival was longer (median, 48 vs. 29 weeks, P = 0.02) among the patients who received dacarbazine plus tamoxifen than among those who received dacarbazine alone. Among women, both the response rate (38 percent vs. 10 percent, P = 0.04) and the median survival (69 vs. 30 weeks, P = 0.008) were better with dacarbazine plus tamoxifen than with dacarbazine alone, whereas among men the differences were smaller and not statistically significant. Among the patients given dacarbazine alone, there were no significant differences between women and men in response rate (10 percent vs. 13 percent) or survival (30 vs. 27 weeks), whereas among those given dacarbazine plus tamoxifen, women had better outcomes, as indicated by both response rate (38 percent vs. 19 percent, P = 0.15) and survival (69 vs. 31 weeks, P = 0.02). When we analyzed the Quetelet body-mass index (the weight in kilograms divided by the square of the height in meters) as an indirect indicator of the levels of endogenous estrogens in postmenopausal women and in men, survival was not affected by the body-mass index in the group given dacarbazine alone, whereas in the group given dacarbazine plus tamoxifen, survival was longer among patients whose Quetelet index was above the median value than among those with a Quetelet index lower than the median value (60 vs. 26 weeks, P

AB - Background. Endocrine factors may affect the clinical course of malignant melanoma and the response to the treatment of this disease. The presence of estrogen receptors in melanomas has been suggested, and occasional responses to antiestrogen therapy have been reported. Methods and Results. We randomly assigned 117 patients with metastatic malignant melanoma to treatment with dacarbazine alone or dacarbazine in combination with tamoxifen. The overall rate of response, measured objectively, was higher (28 percent vs. 12 percent, P = 0.03) and survival was longer (median, 48 vs. 29 weeks, P = 0.02) among the patients who received dacarbazine plus tamoxifen than among those who received dacarbazine alone. Among women, both the response rate (38 percent vs. 10 percent, P = 0.04) and the median survival (69 vs. 30 weeks, P = 0.008) were better with dacarbazine plus tamoxifen than with dacarbazine alone, whereas among men the differences were smaller and not statistically significant. Among the patients given dacarbazine alone, there were no significant differences between women and men in response rate (10 percent vs. 13 percent) or survival (30 vs. 27 weeks), whereas among those given dacarbazine plus tamoxifen, women had better outcomes, as indicated by both response rate (38 percent vs. 19 percent, P = 0.15) and survival (69 vs. 31 weeks, P = 0.02). When we analyzed the Quetelet body-mass index (the weight in kilograms divided by the square of the height in meters) as an indirect indicator of the levels of endogenous estrogens in postmenopausal women and in men, survival was not affected by the body-mass index in the group given dacarbazine alone, whereas in the group given dacarbazine plus tamoxifen, survival was longer among patients whose Quetelet index was above the median value than among those with a Quetelet index lower than the median value (60 vs. 26 weeks, P

UR - http://www.scopus.com/inward/record.url?scp=0026625695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026625695&partnerID=8YFLogxK

M3 - Article

C2 - 1635566

AN - SCOPUS:0026625695

VL - 327

SP - 516

EP - 523

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 8

ER -